Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
CD4 T-cell counts
Humoral response
People living with HIV
SARS-CoV-2
Vaccine
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
25
02
2022
revised:
13
05
2022
accepted:
14
05
2022
pubmed:
1
6
2022
medline:
27
10
2022
entrez:
31
5
2022
Statut:
ppublish
Résumé
The aim of this study was to assess the immunogenicity of SARS-CoV-2 available vaccines among people living with HIV (PLWH) after a complete vaccination scheme, and determine predictors of seroconversion. This multicentre prospective cohort study included 420 PLWH who had received a standard immunization, either with mRNA or adenoviral-vectored COVID-19 vaccines. Antibody response was evaluated within 1 to 2 months after the last dose of the vaccine with a quantitative determination of antitrimeric spike protein-specific IgG antibodies and IgG neutralizing antibodies. Overall, 384 of 420 PLWH (91%) showed antibody response to vaccination. Seroconversion was observed in 308 of 326 individuals with cluster of differentiation 4 (CD4) counts ≥350 cells/mm HIV-related immunosuppression impairs the antibody response to SARS-CoV-2 vaccines. Specific vaccination schemes should be urgently tailored in this setting, particularly in patients with CD4 cell counts <200 cells/μL. Adenoviral-vectored vaccines should be avoided in PLWH whenever possible.
Identifiants
pubmed: 35640840
pii: S1198-743X(22)00276-2
doi: 10.1016/j.cmi.2022.05.018
pmc: PMC9144847
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Antibodies, Viral
0
Antibodies, Neutralizing
0
Immunoglobulin G
0
RNA, Messenger
0
spike protein, SARS-CoV-2
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1492-1498Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.
Références
AIDS. 2021 Sep 1;35(11):1872-1874
pubmed: 33993131
Clin Infect Dis. 2022 Apr 9;74(7):1268-1270
pubmed: 34293114
Nat Commun. 2021 Oct 5;12(1):5839
pubmed: 34611163
Vaccine. 2022 Jun 9;40(26):3633-3637
pubmed: 35568588
Clin Infect Dis. 2014 Apr;58(8):1130-9
pubmed: 24415637
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Sci Immunol. 2020 Dec 23;5(54):
pubmed: 33361161
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853
AIDS. 2022 Mar 15;36(4):F1-F5
pubmed: 35013085
Clin Microbiol Infect. 2022 May;28(5):755-756
pubmed: 35150883
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Respir Med. 2021 Dec;9(12):1450-1466
pubmed: 34688434
Sci Rep. 2021 Nov 23;11(1):22777
pubmed: 34815503
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
J Intern Med. 2022 Apr;291(4):513-518
pubmed: 34841629
Clin Microbiol Infect. 2021 Nov;27(11):1678-1684
pubmed: 34186209
Clin Microbiol Infect. 2021 Dec;27(12):1851-1855
pubmed: 34438069
EBioMedicine. 2021 Dec;74:103705
pubmed: 34861491
Lancet HIV. 2021 Jun;8(6):e317-e318
pubmed: 34087093
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Lancet HIV. 2021 Aug;8(8):e474-e485
pubmed: 34153264
Immunol Rev. 2013 Jul;254(1):78-101
pubmed: 23772616
Clin Chem Lab Med. 2020 Jul 28;58(8):1357-1364
pubmed: 32447328